Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series

NCT06742307 is registered in ClinicalTrials.gov with Hospital Authority, Hong Kong as lead sponsor.

NCT NCT06742307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06742307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series
Lead sponsor
Hospital Authority, Hong Kong
Phase
Phase 4
Overall status
Recruiting
Start date
August 21, 2025
Completion date
February 1, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration choroidal neovascularization